1. Accueil
  2. Groupes / réseaux
  3. COMETE - Cancers de la surrénale

Recherche et Publications – ENDOCAN COMETE-Cancer

Etudes cliniques

Le Réseau recrute les patients: tumeurs/échantillons biologiques pour des Etudes Cliniques de trois types :

  • Essais Thérapeutiques
  • Etudes Cliniques/Translationnelles

Pour toute information, contactez le Dr Rossella Libé: Mail Libé

ESSAIS THERAPEUTIQUES

Corticosurrénalomes

Participation française à l’essai thérapeutique intérnational: ADIUVO-2

Traitement adjuvant par mitotane vs mitotane associé au cisplatine/etoposide après chirurgie complète dans les carcinomes corticosurrénalien à haut risque de récidive: une étude pragmatique, randomisée de phase 3 avec un groupe observationnel.
Promoteur : APHP-PHRC-K Cancer INCa 2019
Coordonnateur: Rossella Libé Date de début : 2022 Date de fin prévue : 2022 Nombre patients prévus : n=4 Centres du Réseau ENDOCAN-COMETE: Cochin, IGR, Bordeaux, Grenoble, Marseille, Angers, Lyon, Strasbourg, Besançon, Reims, Toulouse, Nantes, Brest, Dijon, Montpellier, Poitiers, Nancy
Statut : en cours d’ouverture

Phéochromocytomes/Paragangliomes malins

Participation française à l’essai thérapeutique MK6482-015
Etude de phase 2 évaluant l’efficacité et la sécurité d’emploi du Belzutifan (MK-6482, anciennement PT2977) en monothérapie chez des patients atteints d’un phéochromocytome/paragangliome (PPGL) avancé ou d’une tumeur neuroendocrine du pancréas (TNEp)
Promoteur :MERCK Coordonnateur: Julien Hadoux (France)
Date de début : 2021 Date de fin : 2025 Nombre patients prévus (étude internationale) : n=70
Centres du Réseau ENDOCAN-COMETE: Cochin, IGR, Marseille, Lyon, Strasbourg,
Statut : Actuellement en cours

 

Cancers corticosurrénaliens et PPM

Essai de phase 1/2 sur l’EO2401, un nouveau vaccin thérapeutique peptidique d’origine microbienne, en association avec le blocage du point de contrôle PD-1, pour le traitement des patients atteins de corticosurrénalome métastatique ou localement avancé ou d’un phéochromocytome / paragangliome malin : SPENCER.
Promoteur :ENTEROME Coordonnateur: Eric Baudin (France)
Date de début : 2021 Date de fin : 2023 Nombre patients prévus (étude internationale) : n=72
Centres du Réseau ENDOCAN-COMETE: IGR, Lyon,

Statut : Actuellement en cours

 

ETUDES CLINIQUES EN COURS

Cancers corticosurrénaliens

  • RETRACC – RETRospective AdrenoCortical Carcinoma
    Responsable : Matthieu Faron (Gustave Roussy)
  • PROSACC- Prospective registry of surgical management in localized ACC (ENSAT stage 1-2-3) based on ENSAT registry- “PROSACC”
    Responsable : Rossella Libé (Cochin)
  • IMPACT COMETE : IMPACT THERAPEUTIQUE DU RESEAU COMETE CANCER DE LA SURRENALE DANS LA PRISE EN CHARGE DES CORTICOSURRENALOMES- Réseau FRANCIM
    Responsable : Rossella Libé (Cochin)
  • Histoire naturelle des ACC incidentaux
    Responsable : Magalie Haissaguerre Antoine Tabarin (Bordeaux)
  • Etude sur les approches loco-régionaux dans les corticosurrénalomes pauci-métastatiques.
    Responsable: Charles Roux (IGR)

PPM

  • Expérience lyonnaise sur les PGGS cervicaux et proposition de cohorte
    Responsable : Juliette Abeillon, Helene Lasolle, Françoise Borson Chazot, (Lyon)
  • Neuroblastome/Phéochromocytomes composites : un Observatoire rétrospectif des tumeurs neuroblastiques périphériques diagnostiquées après l’âge de 15 ans
    Responsable : Orlane Magnier (Grenoble), Karine Renaudin (Nantes)
  • MAPP-P-network- A MAlignant Pheochromocytoma and Paraganglioma unique large Prospective cohort of the French ENDOCAN COMETE network “Epidémiologie thérapeutique en vie réelle d’un réseau”)
    Responsable: Dr Sophie Moog (IGR) – Dr Eric Baudin – ENDOCAN COMETE
  • Etat des lieux des pratiques d’anesthésie concernant la prise en charge des phéochromocytomes lors de traitement interventionnel (Chirurgie, radiofréquence, cimentoplastie, cryothérapie).
    Responsables : Jean-Philippe Rives et Migena Demiri (IGR)
  • Etude de cohorte de patients avec PGL ou PHEO multifocal négatif pour les analyses génétiques (panel 1 et 2) : phénotype clinique, biochimique et en imagerie.
    Responsable : David Taieb (Marseille)
  • Abstention chirurgicale dans les récidives de phéochromocytomes génétiquement déterminés
    Responsable : Marie Puerto (Bordeaux)

RECHERCHE TRANSLATIONNELLE

  • COMETE Care- Implementing COMETE markers in adrenal cancers patients
    Responsable : Guillaume Assié (Cochin)

Principales publications du réseau

  • Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-G10. doi: 10.1530/EJE-16-0033.
  • Lussey-Lepoutre C, Bellucci A, Morin A, Buffet A, Amar L, Janin M, Ottolenghi C, Zinzindohoué F, Autret G, Burnichon N, Robidel E, Banting B, Fontaine S, Cuenod CA, Benit P, Rustin P, Halimi P, Fournier L, Gimenez-Roqueplo AP, Favier J, Tavitian B. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma. Clin Cancer Res. 2016 Mar 1;22(5):1120-9. doi: 10.1158/1078-0432.CCR-15-1576. Epub 2015 Oct 21.
  • Gravel G, Niccoli P, Rohmer V, Moulin G, Borson-Chazot F, Rousset P, Pasco-Papon A, Marcus C, Dubrulle F, Gouya H, Bidault F, Dupas B, Gabrillargues J, Caumont-Prim A, Hernigou A, Gimenez-Roqueplo AP, Halimi P. The value of a rapid contrast-enhanced angio-MRI protocol in the detection of head and neck paragangliomas in SDHx mutations carriers: a retrospective study on behalf of the PGL.EVA investigators. Eur Radiol. 2016 Jun;26(6):1696-704.
  • Drelon C, Berthon A, Mathieu M, Ragazzon B, Kuick R, Tabbal H, Septier A, Rodriguez S, Batisse-Lignier M, Sahut-Barnola I, Dumontet T, Pointud JC, Lefrançois-Martinez AM, Baron S, Giordano TJ, Bertherat J, Martinez A, Val P. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum Mol Genet. 2016 May 5. pii: ddw136.
  • Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ, Verhaak RG. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 May 9;29(5):723-36. doi: 10.1016/j.ccell.2016.04.002
  • Lussey-Lepoutre C, Hollinshead KE, Ludwig C, Menara M, Morin A, Castro-Vega LJ, Parker SJ, Janin M, Martinelli C, Ottolenghi C, Metallo C, Gimenez-Roqueplo AP, Favier J, Tennant DA. Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun. 2015 Nov 2;6:8784
  • de Corbière P, Ritzel K, Cazabat L, Ropers J, Schott M, Libé R, Koschker AC, Leboulleux S, Deutschbein T, Do Cao C, Hahner S, Drui D, Miehle K, Caron P, Waldmann J, Chabre O, Quinkler M, Touraine P, Villares Fragoso MC, Bertherat J, Bertagna X, Fassnacht M, Raffin-Sanson ML. Pregnancy in Women Previously Treated  for an Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2015 Dec;100(12):4604-11. doi: 10.1210/jc.2015-2341. Epub 2015 Oct 13. PubMed PMID: 26461265.
  • Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J,Volante M, Quinkler M, Chabre O, Bala M, Tabarin A, Beuschlein F, Vezzosi D,Deutschbein T, Borson-Chazot F, Hermsen I, Stell A, Fottner C, Leboulleux S,Hahner S, Mannelli M, Berruti A, Haak H, Terzolo M, Fassnacht M, Baudin E; ENSAT network. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015 Oct;26(10):2119-25. doi: 10.1093/annonc/mdv329. PubMed PMID: 26392430.
  • Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015 Jul 3;3:45. doi: 10.3389/fcell.2015.00045. eCollection 2015. Review. PubMed PMID: 26191527; PubMed Central PMCID: PMC4490795.
  • Baudin E; Endocrine Tumor Board of Gustave Roussy. Adrenocortical carcinoma. Endocrinol Metab Clin North Am. 2015 Jun;44(2):411-34. doi: 10.1016/j.ecl.2015.03.001. Review. Erratum in: Endocrinol Metab Clin North Am. 2015 Sep;44(3):xix. multiple investigator names added. PubMed PMID: 26038209.
  • Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libé R, Ardito  A, Al Ghuzlan A, Quinkler M, Oßwald A, Ronchi CL, de Krijger R, Feelders RA, Waldmann J, Willenberg HS, Deutschbein T, Stell A, Reincke M, Papotti M, Baudin E, Tissier F, Haak HR, Loli P, Terzolo M, Allolio B, Müller HH, Fassnacht M. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015 Mar;100(3):841-9. doi: 10.1210/jc.2014-3182. Epub 2015 Jan 5. PubMed PMID: 25559399.
  • Loriot C, Domingues M, Berger A, Menara M, Ruel M, Morin A, Castro-Vega LJ, Letouzé É, Martinelli C, Bemelmans AP, Larue L, Gimenez-Roqueplo AP, Favier J. Deciphering the molecular basis of invasiveness in Sdhb-deficient cells. Oncotarget. 2015 Oct 20;6(32):32955-65. doi: 10.18632/oncotarget.5106. PubMed PMID: 26460615; PubMed Central PMCID: PMC4741742.
  • Leinhäuser I, Richter A, Lee M, Höfig I, Anastasov N, Fend F, Ercolino T, Mannelli M, Gimenez-Roqueplo AP, Robledo M, de Krijger R, Beuschlein F, Atkinson  MJ, Pellegata NS. Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget. 2015 Nov 17;6(36):39111-26. doi: 10.18632/oncotarget.4912. PubMed PMID: 26337467; PubMed Central PMCID: PMC4770760.
  • Lepoutre-Lussey C, Thibault C, Buffet A, Morin A, Badoual C, Bénit P, Rustin P, Ottolenghi C, Janin M, Castro-Vega LJ, Trapman J, Gimenez-Roqueplo AP, Favier  J. From Nf1 to Sdhb knockout: Successes and failures in the quest for animal models of pheochromocytoma. Mol Cell Endocrinol. 2016 Feb 5;421:40-8. doi: 10.1016/j.mce.2015.06.027. Epub 2015 Jun 27. PubMed PMID: 26123588.
  • Gimenez-Roqueplo AP. [Pheochromocytoma and paraganglioma]. Rev Prat. 2015 Jun;65(6):826-30. French. PubMed PMID: 26298909.
  • Castro-Vega LJ, Lepoutre-Lussey C, Gimenez-Roqueplo AP, Favier J. Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene. 2016Mar 3;35(9):1080-9. doi: 10.1038/onc.2015.172. Epub 2015 Jun 1. Review. PubMed PMID: 26028031.
  • Oudijk L, Neuhofer CM, Lichtenauer UD, Papathomas TG, Korpershoek E, Stoop H, Oosterhuis JW, Smid M, Restuccia DF, Robledo M, de Cubas AA, Mannelli M,Gimenez-Roqueplo AP, Dinjens WN, Beuschlein F, de Krijger RR. Immunohistochemicalexpression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. Eur J Endocrinol. 2015 Jul;173(1):43-52. doi: 10.1530/EJE-14-1164. Epub 2015 Apr 27. PubMed PMID: 25916394.
  • de Cubas AA, Korpershoek E, Inglada-Pérez L, Letouzé E, Currás-Freixes M, Fernández AF, Comino-Méndez I, Schiavi F, Mancikova V, Eisenhofer G, Mannelli M, Opocher G, Timmers H, Beuschlein F, de Krijger R, Cascon A, Rodríguez-Antona C, Fraga MF, Favier J, Gimenez-Roqueplo AP, Robledo M. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clin Cancer Res. 2015 Jul 1;21(13):3020-30. doi: 10.1158/1078-0432.CCR-14-2804.Epub 2015 Mar 30. PubMed PMID: 25825477.
  • Oudijk L, van Nederveen F, Badoual C, Tissier F, Tischler AS, Smid M, Gaal J,Lepoutre-Lussey C, Gimenez-Roqueplo AP, Dinjens WN, Korpershoek E, de Krijger R, Favier J. Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas. PLoS One. 2015 Mar 20;10(3):e0121361. doi:  10.1371/journal.pone.0121361. eCollection 2015. PubMed PMID: 25794004; PubMed Central PMCID: PMC4368716.
  • Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, Tissier F, Volante M, Matias-Guiu X, Smid M, Favier J, Rapizzi E, Libe R, Currás-Freixes M, Aydin S, Huynh T, Lichtenauer U, van Berkel A, Canu L, Domingues R, Clifton-Bligh RJ, Bialas M, Vikkula M, Baretton G, Papotti M, Nesi G, Badoual C, Pacak K, Eisenhofer G, Timmers HJ, Beuschlein F, Bertherat J, Mannelli M, Robledo M, Gimenez-Roqueplo AP, Dinjens WN, Korpershoek E, de Krijger RR. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: aMultinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015 Jun;28(6):807-21. doi: 10.1038/modpathol.2015.41. Epub  2015 Feb 27. PubMed PMID: 25720320.
  • Lepoutre-Lussey C, Caramella C, Bidault F, Déandreis D, Berdelou A, Al Ghuzlan A, Hartl D, Borget I, Gimenez-Roqueplo AP, Dumont F, Deschamps F, Nascimento C, Lumbroso J, Guillaud Bataille M, Schlumberger M, Baudin E, Leboulleux S. Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur J Nucl Med Mol Imaging. 2015 May;42(6):868-76. doi: 10.1007/s00259-015-3003-z. Epub 2015 Feb 13. PubMed PMID: 25676472.
  • Castro-Vega LJ, Letouzé E, Burnichon N, Buffet A, Disderot PH, Khalifa E, Loriot C, Elarouci N, Morin A, Menara M, Lepoutre-Lussey C, Badoual C, Sibony M,  Dousset B, Libé R, Zinzindohoue F, Plouin PF, Bertherat J, Amar L, de Reyniès A,  Favier J, Gimenez-Roqueplo AP. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015 Jan 27;6:6044. doi: 10.1038/ncomms7044. PubMed PMID: 25625332; PubMed Central PMCID: PMC4354166.
  • de Krijger RE, Bertherat J. 5th International ACC Symposium: Classification of Adrenocortical Cancers from Pathology to Integrated Genomics: Real Advances or Lost in Translation? Horm Cancer. 2016 Feb;7(1):3-8. doi:10.1007/s12672-015-0242-1. Epub 2015 Dec 16. PubMed PMID: 26676358.
  • Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, Young J, Paci A, Baudin E, Lombès M. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2015 Aug;100(8):2890-8. doi: 10.1210/JC.2015-2080. Epub 2015 Jun 29. PubMed PMID: 26120791.
  • Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015Apr;16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18. PubMed PMID: 25795408.
  • Hescot S, Paci A, Seck A, Slama A, Viengchareun S, Trabado S, Brailly-Tabard S, Al Ghuzlan A, Young J, Baudin E, Lombès M. The lack of antitumor effects of o,p’DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer. 2014 Oct;5(5):312-23. doi:10.1007/s12672-014-0189-7. Epub 2014 Jul 16. PubMed PMID: 25026941.
  • Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014 Sep;171(3):R111-22. doi: 10.1530/EJE-14-0113. Epub 2014 Jun 2.Review. PubMed PMID: 24891137.
  • Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, Williams AR, Ardito A, Leboulleux S, Volante M, Deutschbein T, Feelders R, Ronchi C, Grisanti S, Gelderblom H, Porpiglia F, Papotti M, Hammer GD, Allolio B, Terzolo M. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014 Apr;65(4):832-8. doi: 10.1016/j.eururo.2013.11.006. Epub 2013 Nov 14. PubMed PMID: 24268504.
  • Menara M, Oudijk L, Badoual C, Bertherat J, Lepoutre-Lussey C, Amar L, Iturrioz X, Sibony M, Zinzindohoué F, de Krijger R, Gimenez-Roqueplo AP, Favier J. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. J Clin Endocrinol Metab. 2015 Feb;100(2):E287-91.doi: 10.1210/jc.2014-1870. Epub 2014 Nov 18. PubMed PMID: 25405498.
  • Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5. PubMed PMID: 24752622.
  • Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H,Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J.Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014 Jun;46(6):607-12. doi: 10.1038/ng.2953. Epub 2014 Apr 20. PubMed PMID: 24747642.
  • Ragazzon B, Libé R, Assié G, Tissier F, Barreau O, Houdayer C, Perlemoine K, Audebourg A, Clauser E, René-Corail F, Bertagna X, Dousset B, Bertherat J, Groussin L. Mass-array screening of frequent mutations in cancers reveals RB1alterations in aggressive adrenocortical carcinomas. Eur J Endocrinol. 2014 Feb 4;170(3):385-91. doi: 10.1530/EJE-13-0778. Print 2014 Mar. PubMed PMID: 24347427.
  • Libé R, Arlt W, Louiset E, Waintrop C, Guibourdenche J, Sibony M, Clauser E, Groussin L. A feminizing adrenocortical carcinoma in the context of a late onset 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014 Jun;99(6):1943-4. doi:10.1210/jc.2014-1342. Epub 2014 Mar 21. PubMed PMID: 24654754.
  • Coste J, Tissier F, Pouchot J, Ecosse E, Rouquette A, Bertagna X, Libé R,Viallon V. Rasch analysis for assessing unidimensionality and identifyingmeasurement biases of malignancy scores in oncology. The example of the Weiss histopathological system for the diagnosis of adrenocortical cancer. Cancer Epidemiol. 2014 Apr;38(2):200-8. doi: 10.1016/j.canep.2014.02.004. Epub 2014 Mar  14. PubMed PMID: 24631426.
  • Libé R, Assié G. [Adrenocortical carcinoma: Update in 2014]. Presse Med. 2014 Apr;43(4 Pt 1):401-9. doi: 10.1016/j.lpm.2014.01.009. Epub 2014 Mar 7. Review. French. PubMed PMID: 24613316.
  • Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015 Feb;11(2):101-11. doi: 10.1038/nrendo.2014.188. Epub 2014 Nov 11. Review. PubMed PMID: 25385035.
  • Couvé S, Ladroue C, Laine E, Mahtouk K, Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, Lecomte B, Pagès JC, Collin C, Lasne F, Benusiglio PR,Bressac-de Paillerets B, Feunteun J, Lazar V, Gimenez-Roqueplo AP, Mazure NM,Dessen P, Tchertanov L, Mole DR, Kaelin W, Ratcliffe P, Richard S, Gardie B.Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. Cancer Res. 2014 Nov 15;74(22):6554-64. doi:10.1158/0008-5472.CAN-14-1161. Epub 2014 Nov 4. PubMed PMID: 25371412.
  • Rafat C, Zinzindohoue F, Hernigou A, Hignette C, Favier J, Tenenbaum F, Gimenez-Roqueplo AP, Plouin PF, Amar L. Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery. J Clin Endocrinol Metab. 2014 Dec;99(12):E2681-5. doi: 10.1210/jc.2014-1975. PubMedPMID: 25188716.
  • Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. PubMed PMID:24893135.
  • Castro-Vega LJ, Buffet A, De Cubas AA, Cascón A, Menara M, Khalifa E, Amar L, Azriel S, Bourdeau I, Chabre O, Currás-Freixes M, Franco-Vidal V,Guillaud-Bataille M, Simian C, Morin A, Letón R, Gómez-Graña A, Pollard PJ,Rustin P, Robledo M, Favier J, Gimenez-Roqueplo AP. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet. 2014 May 1;23(9):2440-6. doi: 10.1093/hmg/ddt639. Epub 2013 Dec 13. PubMedPMID: 24334767.
  • Buffet A, Smati S, Mansuy L, Ménara M, Lebras M, Heymann MF, Simian C, Favier  J, Murat A, Cariou B, Gimenez-Roqueplo AP. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab. 2014 Feb;99(2):E369-73. doi: 10.1210/jc.2013-2600. Epub 2013 Nov 25. PubMed PMID:24276449.
  • Mediouni A, Ammari S, Wassef M, Gimenez-Roqueplo AP, Laredo JD, Duet M, Tran Ba Huy P, Oker N. Malignant head/neck paragangliomas. Comparative study. Eur Ann Otorhinolaryngol Head Neck Dis. 2014 Jun;131(3):159-66. doi:10.1016/j.anorl.2013.05.003. Epub 2013 Nov 14. PubMed PMID: 24239180.
  • Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C, Treatment of malignant pheochromocytoma and paraganglioma Eur J Endocrinol. 2014 Sep;171(3):R111-22. doi: 10.1530/EJE-14-0113. Epub 2014 Jun 2. Review.
  • Denorme M, Yon L, Roux C, Gonzalez BJ, Baudin E, Anouar Y and Dubessy C Both Sunitinib and Sorafenib are Effective Treatments for Pheochromocytoma in a Xenograft Model Cancer Lett. 2014 Oct 1;352(2):236-44. doi: 10.1016/j.canlet.2014.07.005. Epub 2014 Jul 9
  • Hescot S, Paci A, Seck A, Slama A, Viengchareun S, Trabado S, Brailly-Tabard S, Al Ghuzlan A, Young J, Baudin E, Lombès M  The lack of antitumor effects of o,p’DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. Horm Cancer. 2014 Oct;5(5):312-23. doi: 10.1007/s12672-014-0189-7. Epub 2014 Jul 16.
  • Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma.Nat Genet. 2014 Apr 20. doi: 10.1038/ng.2953.
  • Barreau O, Assié G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, René-Corail F, Bertagna X, Dousset B, Hamzaoui N, Tissier F, de Reynies A, Bertherat J. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab. 2013 Jan;98(1):E174-84. doi: 10.1210/jc.2012-2993. Epub 2012 Oct 23. PubMed PMID: 23093492.
  • Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, Williams AR, Ardito A, Leboulleux S, Volante M, Deutschbein T, Feelders R, Ronchi C, Grisanti S, Gelderblom H, Porpiglia F, Papotti M, Hammer GD, Allolio B, Terzolo M. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014 Apr;65(4):832-8.doi: 10.1016/j.eururo.2013.11.006. Epub 2013 Nov 14. PubMed PMID: 24268504.
  • Buffet A, Smati S, Mansuy L, Ménara M, Lebras M, Heymann MF, Simian C, Favier J, Murat A, Cariou B, Gimenez-Roqueplo AP. Mosaicism in HIF2A-Related Polycythemia-Paraganglioma Syndrome. J Clin Endocrinol Metab. 2014 Feb;99(2):E369-73. doi: 10.1210/jc.2013-2600. Epub 2013 Nov 25. PubMed PMID:24276449.
  • Chabre O, Libé R, Assie G, Barreau O, Bertherat J, Bertagna X, Feige JJ,Cherradi N. Serum miR-483-5p and miR-195 are predictive of recurrence risk inadrenocortical cancer patients. Endocr Relat Cancer. 2013 Jul 5;20(4):579-94.doi: 10.1530/ERC-13-0051. Print 2013 Aug. PubMed PMID: 23756429.
  • Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O’Neil DM, Libé R,Allolio B, Bertagna X, Bertherat J, Beuschlein F, Fassnacht M, Karavitaki N,Mannelli M, Mantero F, Opocher G, Porfiri E, Quinkler M, Sherlock M, Terzolo M,Nightingale P, Shackleton CH, Stewart PM, Hahner S, Arlt W. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5?-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol  Metab. 2013 Jan;98(1):161-71. doi: 10.1210/jc.2012-2851. Epub 2012 Nov 16. PubMedPMID: 23162091.
  • De Martino MC, Al Ghuzlan A, Aubert S, Assié G, Scoazec JY, Leboulleux S, DoCao C, Libè R, Nozières C, Lombès M, Pattou F, Borson-Chazot F, Hescot S, Mazoyer C, Young J, Borget I, Colao A, Pivonello R, Soria JC, Bertherat J, Schlumberger M, Lacroix L, Baudin E. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab. 2013Oct;98(10):4080-8. doi: 10.1210/jc.2013-2165. Epub 2013 Aug 26. PubMed PMID:23979958.
  • Favier J, Letouzé E. [Mutations in succinate dehydrogenase and DNAmethylation]. Med Sci (Paris). 2013 Dec;29(12):1092-4. doi:10.1051/medsci/20132912010. Epub 2013 Dec 20. French. PubMed PMID: 24356137.
  • Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefèvre L,Guillaud-Bataille M, Beuschlein F, Tissier F, Bertherat J, Rizk-Rabin M, Ragazzon B. Silencing mutated ?-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS One.2013;8(2):e55743. doi: 10.1371/journal.pone.0055743. Epub 2013 Feb 7. PubMedPMID: 23409032; PubMed Central PMCID: PMC3567123.
  • Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, Niccoli P, Leboulleux S, Amar L, Borson-Chazot F, Cardot-Bauters C, Delemer B, Chabolle F, Coupier I, Libé R, Peitzsch M, Peyrard S, Tenenbaum F, Plouin PF, Chatellier G, Rohmer V. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013 Jan;98(1):E162-73. doi: 10.1210/jc.2012-2975. Epub 2012 Nov 15. PubMed PMID: 23162105.
  • Hadoux, Julien;Favier, Judith; Scoazec, Jean Yves; Leboulleux, Sophie; Al Ghuzlan, Abir; Caramella, Caroline; Déandreis, Désirée; Borget, Isabelle; Loriot, Céline; Chougnet, Cécile; Letouzé, Eric; Young,Jacques; Amar, Laurence; Bertherat, Jérôme; Libé, Rossella; Dumont, Frédéric; Deschamps, Frédéric; Schlumberger, Martin; Gimenez-Roqueplo, Anne-Paule; Baudin, Eric SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma and paraganglioma Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5.
  • Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de laFouchardiere C, Libé R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E; French group of Endocrine and Adrenal tumors (Groupe des Tumeurs Endocrines-REseau NAtional des Tumeurs ENdocrines and COrtico-MEdullo Tumeurs Endocrines networks). One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2013Oct;98(10):4006-12. doi: 10.1210/jc.2013-1907. Epub 2013 Jul 24. PubMed PMID:23884775.
  • Hescot S, Slama A, Lombès A, Paci A, Remy H, Leboulleux S, Chadarevian R,Trabado S, Amazit L, Young J, Baudin E, Lombès M. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 May 21;20(3):371-81. doi:10.1530/ERC-12-0368. Print 2013 Jun. PubMed PMID: 23696597.
  • Jamilloux Y, Favier J, Pertuit M, Delage-Corre M, Lopez S, Teissier MP,Mathonnet M, Galinat S, Barlier A, Archambeaud F. A MEN1 syndrome with a paraganglioma. Eur J Hum Genet. 2014 Feb;22(2):283-5. doi: 10.1038/ejhg.2013.128. Epub 2013 Jun 19. PubMed PMID: 23778871; PubMed Central PMCID: PMC3895646.
  • Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH,Skogseid B, Leboulleux S, Mantero F, Haak HR, Fassnacht M. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013 Dec;98(12):4759-67. doi:10.1210/jc.2013-2281. Epub 2013 Sep 20. PubMed PMID: 24057287.
  • Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P, Buffet A, Marcaillou C, Bertherat J, Amar L, Rustin P, De Reyniès A, Gimenez-Roqueplo AP, Favier J. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013 Jun 10;23(6):739-52. doi: 10.1016/j.ccr.2013.04.018. Epub 2013 May 23. PubMed PMID:23707781.
  • Ederhy S, Cohen A, Dufaitre G, Chaderevian R, Abbas H, Bertagna X, Libé R. No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. J Endocrinol Invest. 2012 Nov;35(10):911-4. doi:10.3275/8616. Epub 2012 Sep 24. PubMed PMID: 23013780.
  • Tissier F, Aubert S, Leteurtre E, Al Ghuzlan A, Patey M, Decaussin M, Doucet L, Gobet F, Hoang C, Mazerolles C, Monges G, Renaudin K, Sturm N, Trouette H,Vacher-Lavenu MC, Viallon V, Baudin E, Bertagna X, Coste J, Libe R.Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE. Am J Surg Pathol. 2012 Aug;36(8):1194-201. doi: 10.1097/PAS.0b013e31825a6308. PubMed PMID:  22790860.
  • Loriot C, Burnichon N, Gadessaud N, Vescovo L, Amar L, Libé R, Bertherat J,Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP, Favier J. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J Clin Endocrinol Metab. 2012 Jun;97(6):E954-62. doi: 10.1210/jc.2011-3437. Epub 2012 Apr 4. PubMed PMID: 22492777.
  • Favier J, Igaz P, Burnichon N, Amar L, Libé R, Badoual C, Tissier F, Bertherat J, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012 Mar;23(1):34-42. doi: 10.1007/s12022-011-9189-0. PubMed PMID: 22183643.
  • Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G; ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii131-8. PubMed PMID: 22997446.
  • Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012 Nov;97(11):4040-50. doi: 10.1210/jc.2012-2356. Epub 2012 Sep 10. PubMed PMID: 22965939; PubMed Central PMCID: PMC3683800.
  • Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H,Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group.Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/ NEJMoa1200966. Epub 2012 May 2. PubMed PMID: 22551107.
  • Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res. 2012 May;44(5):390-9. doi: 10.1055/s-0031-1299707. Epub 2012 Feb 7. Review. PubMed PMID: 22314389.
  • Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S,Volante M, Daffara F, Generali D, Leboulleux S, Perotti P, Baudin E, Papotti M,Terzolo M. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012 Mar;166(3):451-8. doi: 10.1530/EJE-11-0918. Epub 2011 Dec 21. PubMed PMID:22189997.
  • Mauclère-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A,Deandreis D, Drouard L, Tabarin A, Chanson P, Schlumberger M, Baudin E. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol. 2012 Feb;166(2):261-8. doi: 10.1530/EJE-11-0557. Epub 2011 Nov 2. PubMed PMID:22048971.
  • Gaujoux S, Bertherat J, Dousset B, Groussin L. Laparoscopic adrenalectomy for adrenocortical carcinoma: a medico-surgical perspective. Ann Endocrinol (Paris). 2012 Nov;73(5):441-7. doi: 10.1016/j.ando.2012.07.001. Epub 2012 Sep 7. Review.PubMed PMID: 22959492.
  • Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, de Joussineau C, Batisse-Lignier M, Lefrançois-Martinez AM, Bertherat J, Martinez A, Val P. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One. 2012;7(8):e44171. doi: 10.1371/journal.pone.0044171. Epub2012 Aug 28. PubMed PMID: 22952916; PubMed Central PMCID: PMC3429465.
  • Burnichon N, Cascón A, Schiavi F, Morales NP, Comino-Méndez I, Abermil N,Inglada-Pérez L, de Cubas AA, Amar L, Barontini M, de Quirós SB, Bertherat J,Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, Chanson P, Chiara MD,Corssmit EP, Giacchè M, de Krijger RR, Ercolino T, Girerd X, Gómez-García EB,Gómez-Graña A, Guilhem I, Hes FJ, Honrado E, Korpershoek E, Lenders JW, Letón R, Mensenkamp AR, Merlo A, Mori L, Murat A, Pierre P, Plouin PF, Prodanov T,Quesada-Charneco M, Qin N, Rapizzi E, Raymond V, Reisch N, Roncador G,Ruiz-Ferrer M, Schillo F, Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops CM, Urioste M, Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, Gimenez-Roqueplo AP, Robledo M. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012 May 15;18(10):2828-37. doi: 10.1158/1078-0432.CCR-12-0160. Epub 2012 Mar 27. PubMed PMID: 22452945.
  • Abermil N, Guillaud-Bataille M, Burnichon N, Venisse A, Manivet P, Guignat L, Drui D, Chupin M, Josseaume C, Affres H, Plouin PF, Bertherat J, Jeunemaître X,Gimenez-Roqueplo AP. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab. 2012May;97(5):E805-9. doi: 10.1210/jc.2011-3360. Epub 2012 Mar 14. PubMed PMID:22419703.
  • Assie G, Giordano TJ, Bertherat J. Gene expression profiling in adrenocortical neoplasia. Mol Cell Endocrinol. 2012 Mar 31;351(1):111-7. doi: 10.1016/j.mce.2011.09.044. Epub 2011 Oct 25. Review. PubMed PMID: 22056416.
  • Berthon A, Martinez A, Bertherat J, Val P. Wnt/?-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol. 2012 Mar 31;351(1):87-95. doi: 10.1016/j.mce.2011.09.009. Epub 2011 Sep 10. Review. PubMed PMID: 21930188.
  • Favier J, Buffet A, Gimenez-Roqueplo AP. HIF2A mutations in paraganglioma with polycythemia. N Engl J Med. 2012 Nov 29;367(22):2161; author reply 2161-2. doi:10.1056/NEJMc1211953#SA1. PubMed PMID: 23190243.
  • Burnichon N, Abermil N, Buffet A, Favier J, Gimenez-Roqueplo AP. The genetics  of paragangliomas. Eur Ann Otorhinolaryngol Head Neck Dis. 2012 Dec;129(6):315-8. doi: 10.1016/j.anorl.2012.04.007. Epub 2012 Oct 15. Review. PubMed PMID: 23078982.
  • Burnichon N, Buffet A, Parfait B, Letouzé E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J, Amar L, Vidaud D, Favier J,Gimenez-Roqueplo AP. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet. 2012 Dec 15;21(26):5397-405. doi: 10.1093/hmg/dds374. Epub 2012 Sep 6. PubMed PMID: 22962301.
  • Favier J, Gimenez-Roqueplo AP. [Genetics of paragangliomas and pheochromocytomas]. Med Sci (Paris). 2012 Jun-Jul;28(6-7):625-32. doi: 10.1051/medsci/2012286016. Epub 2012 Jul 16. Review. French. PubMed PMID: 22805139.
  • Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, Le Pottier N, Boussion M,Travers C, Simian C, Burnichon N, Abermil N, Favier J, Jeunemaitre X,Gimenez-Roqueplo AP. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res. 2012 May;44(5):359-66. doi:10.1055/s-0032-1304594. Epub 2012 Apr 19. Review. PubMed PMID: 22517557.
  • Lahlou-Laforêt K, Consoli SM, Jeunemaitre X, Gimenez-Roqueplo AP.Presymptomatic genetic testing in minors at risk of paraganglioma andpheochromocytoma: our experience of oncogenetic multidisciplinary consultation.Horm Metab Res. 2012 May;44(5):354-8. doi: 10.1055/s-0032-1311568. Epub 2012 Apr 19. PubMed PMID: 22517555.
  • Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res. 2012 May;44(5):385-9. doi: 10.1055/s-0031-1301339. Epub 2012 Feb 20. Review. PubMed PMID: 22351478.
  • Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012 May;44(5):328-33. doi: 10.1055/s-0031-1301302. Epub 2012 Feb 10.Review. PubMed PMID: 22328163.
  • Arlt W, Biehl M, Taylor A, Hahner S, Libé R, Hughes B, Schneider P, Smith D, Stiekema H, Krone N, Porfiri E, Opocher G, Bertherat J, Mantero F, Allolio B, Terzolo M, Nightingale P, Shackleton P, Bertagna, Fassnacht M, Stewart P. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011 Dec;96(12):3775-84. doi: 10.1210/jc.2011-1565. Epub 2011 Sep 14
  • Gaujoux S, Bonnet S, Leconte M, Zohar S, Bertherat J, Bertagna X, Dousset B. Risk factors for conversion and complications after unilateral laparoscopic adrenalectomy. Br J Surg. 2011 Oct;98(10):1392-9.
  • Burnichon N, Vescovo L, Amar L, Libé R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011
  • Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP, de Krijger RR. SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. J Clin Endocrinol Metab. 2011;96:E1472-E1476
  • Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR, Baudin E. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J.Clin Endocrinol Metab. 2011 Jun;96(6):1844-51.
  • Fassnacht M, Libé R, Kroiss M, Allolio B; Medscape. Adrenocortical carcinoma: a clinician’s update Nat Rev Endocrinol. 2011 Jun;7(6):323-35.
  • Ragazzon B, Assié G, Bertherat J. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. Endocr Relat Cancer. 2011 Feb 23;18(2):R15-27.
  • Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libé R, Chokri I, Audebourg A, Royer B, Sbiera S, Vacher-Lavenu MC, Dousset B, Bertagna X, Allolio B, Bertherat J, Tissier F. {beta}-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma. Clin Cancer Res. 2011 Jan 15;17(2):328-336.
  • Leboulleux S, Deandreis D, Escourrou C, Al Ghuzlan A, Bidault F, Aupérin A, Travagli JP, Lumbroso J, Schlumberger M, Baudin E. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol. 2011 Jan;164(1):89-94.
  • Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libé R, René-Corail F, Audebourg A, Vacher-Lavenu MC, Groussin L, Bertagna X, Dousset B, Bertherat J, Tissier F. Wnt/{beta}-Catenin Pathway Activation in Adrenocortical Adenomas Is Frequently due to Somatic CTNNB1-Activating Mutations, Which Are Associated with Larger and Nonsecreting Tumors: A Study in Cortisol-Secreting and -Nonsecreting Tumors. J Clin Endocrinol Metab. 2011; 96: E419-E426 .
  • Libé R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin-Sanson ML, Siegel J, Moran J, Drori-Herishanu L, Faucz FR, Lodish M, Nesterova M, Bertagna X, Bertherat J, Stratakis CA. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab. 2011 Jan;96(1):E208-14.
  • Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res. 2010 Nov 1;16(21):5133-41. Epub 2010 Oct 26.
  • Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.Cancer Res. 2010 Nov 1;70(21):8276-81. Epub 2010 Oct 19.
  • Libé R, Coste J, Guignat L, Tissier F, Lefebvre H, Barrande G, Ajzenberg C, Tauveron I, Clauser E, Dousset B, Bertagna X, Bertherat J, Groussin L. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing’s syndrome. Eur J Endocrinol. 2010 Jul;163(1):129-38. Epub 2010 Apr 8.
  • Louiset E, Gobet F, Libé R, Horvath A, Renouf S, Cariou J, Rothenbuhler A, Bertherat J, Clauser E, Grise P, Stratakis CA, Kuhn JM, Lefebvre H. ACTH-independent Cushing’s syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma. J Clin Endocrinol Metab. 2010 Jan;95(1):18-24. Epub 2009 Nov 13.
  • Abiven-Lepage G, Coste J, Tissier F, Groussin L, Billaud L, Dousset B, Goffinet F, Bertagna X, Bertherat J, Raffin-Sanson ML. Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. Eur J Endocrinol. 2010 Nov;163(5):793-800. Epub 2010 Aug 10.
  • Assié G, Guillaud-Bataille M, Ragazzon B, Bertagna X, Bertherat J, Clauser E. The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses.Trends Endocrinol Metab. 2010 May;21(5):325-34.. Review.
  • Favier J, Gimenez-Roqueplo AP. Pheochromocytomas: The (pseudo)-hypoxia hypothesis. Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):957-68
  • Burnichon N, Lepoutre-Lussey C, Laffaire J, Gadessaud N, Molinié V, Hernigou A, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. Eur J Endocrinol. 2011 Jan;164(1):141-5. Epub 2010 Oct 5
  • Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, Jouanno E, Jeunemaitre X, Bénit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010 Aug 1;19(15):3011-20. Epub 2010 May 18.
  • Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J, Plouin PF, de Krijger RR, Gimenez-Roqueplo AP, Dinjens WN. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010 Mar;95(3):1274-8. Epub 2009 Nov 13.
  • Goncalves S, Paupe V, Dassa EP, Brière JJ, Favier J, Gimenez-Roqueplo AP, Bénit P, Rustin P. Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. BMC Biochem. 2010 Jan 28;11:5.
  • Thouënnon E, Pierre A, Tanguy Y, Guillemot J, Manecka DL, Guérin M, Ouafik L, Muresan M, Klein M, Bertherat J, Lefebvre H, Plouin PF, Yon L, Anouar Y. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. Endocr Relat Cancer. 2010 Jun 25;17(3):637-51
  • Plouin PF, Amar L, Lepoutre C. Phaeochromocytomas and functional paragangliomas: Clinical management. Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):933-41.
  • Leboulleux S, Deandreis D, Escourrou C, Al Ghuzlan A, Bidault F, Aupérin A, Travagli JP, Lumbroso J, Schlumberger M, Baudin E. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol. 2011 Jan;164(1):89-94. Epub 2010 Oct 4.
  • Cazejust J, De Baère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S, Baudin E. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol. 2010 Oct;21(10):1527-32.
  • Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer. 2010 Aug 16;17(3):797-807.
  • Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B, Terzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010 Aug 10;28(23):e401-2; author reply e403. Epub 2010 Jun 21. No abstract available.
  • Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010 Jun;162(6):1147-53.
  • Grouzmann E, Drouard-Troalen L, Baudin E, Plouin PF, Muller B, Grand D, Buclin T. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol. 2010 May;162(5):951-60. Epub 2010 Feb 8.
  • Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):261-71. Review.
  • Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, Libe R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X, Tenenbaum F. 18F-FDG PET for the diagnosis of adrenal cortical tumors : a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009;94:1713-1722
  • de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival.  J Clin Oncol. 2009;27:1108-1115
  • Bertagna X., Libe R., Plouin PFP, Baudin E. Le cancer de la surrénale : comment optimiser la prise en charge d’un cancer rare ? UPC INCa Comete Oncologie 10 : 384-386, 2008
  • Bertagna X, Groussin L, Libe R, et Bertherat J Le corticosurrénalome : la prise en charge d’un cancer rare Journées Internationales d’Endocrinologie Clinique. Novembre 2007. Paris.
  • Bertagna X., Groussin L., Libe R., Bertherat, J. Le corticosurrénalome : progrès dans la physiopathologie et la prise en charge d’un cancer rare. Bull. Acad. Natle. Med 192, 87-103, 2008
  • Gimenez-Roqueplo AP, Burnichon N, Amar L, Favier J, Jeunemaitre X, Plouin PF. Achievements of the COMETE program in the genetics of pheochromocytoma Bull Acad Natl Med. 2008 Jan;192(1):105-15;
  • Plouin PF, Gimenez-Roqueplo AP, Bertagna X. COMETE, a network for the study and management of hypersecreting adrenal tumors Bull Acad Natl Med. 2008 Jan;192(1):73-82

© COMETE Septembre 2022